chemieunternehmen.com

Evotec AG is proud to announce the addition of Agilent Technologies‘ RapidFire Mass Spectrometry analysis capabilities to their High Throughput Screening facilities in Hamburg. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-becomes-the-first-contract-research-facility-in-europe-to-offer-agilents-rapidfirems-screening-for-pharmaceutical-drug-discovery-5063

Evotec AG today reported financial results and corporate updates for the first quarter of 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reports-continued-strong-revenue-growth-in-q1-2012-5061

Evotec AG and 4-Antibody AG today announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-and-4-antibody-ag-form-strategic-collaboration-to-innovate-antibody-selection-5059

Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the United States EPA.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-announces-multi-year-agreement-with-the-united-states-environmental-protection-agency-epa-5055

Evotec AG and Conba Pharmaceutical Co., Ltd. announced today the grant of a development and marketing license on EVT 401, a selective, small molecule P2X7 antagonist, for human indications with exception of ophthalmological, chronic obstructive pulmonary disease and endometriosis in China. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-grants-exclusive-rights-on-evt-401-in-china-to-conba-pharmaceutical-5053

Evotec AG today announced that it has extended and expanded its medicinal chemistry collaboration with Active Biotech AB, to further advance an existing programme, which has entered the lead optimisation phase. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-active-biotech-extend-and-expand-medicinal-chemistry-collaboration-5051

Evotec AG today announced the publication of its second edition of DDup, which focuses on neurodegeneration diseases, major disorders with inadequate standards of care.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-2—neurodegenerative-diseases-5048

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2011. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-fy-2011-significant-growth-and-focused-investments-drive-profitability-and-innovation-5047

Evotec AG and IR Pharma today announced that they have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ir-pharma-establish-drug-discovery-alliance-in-the-field-of-respiratory-5043